CytoMed Therapeutics Ltd (GDTC) — Institutional Holders, Q2 2026
3 institutional investment managers reported a GDTC position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $12.2K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
GDTC in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- Axiom Investment ManagementNew · +7,032 sh+$7.2K
Biggest sellers
- XTX Topco LtdSold out · -10,136 sh-$10.4K
- UBS Group AGTrimmed · -1,351 sh-$1.4K
GDTC 13F holders ranked 1–3 of 3
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Axiom Investment Management#1 · 7,032 sh | 7,032 | $7.2K | <0.01% | New |
| 2 | UBS Group AG#2 · 4,831 sh | 4,831 | $5.0K | 0.00% | -21.9% |
| 3 | OSAIC#3 · 21 sh | 21 | $21.00 | 0.00% | 0.0% |
Funds that sold out of GDTC in Q2 2026 (1)
Held GDTC at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| XTX Topco Ltd10,136 sh | 10,136 | $10.1K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.